BG108634A - Injectable compositions for the controlled delivery of pharmacologically active compound - Google Patents
Injectable compositions for the controlled delivery of pharmacologically active compoundInfo
- Publication number
- BG108634A BG108634A BG108634A BG10863404A BG108634A BG 108634 A BG108634 A BG 108634A BG 108634 A BG108634 A BG 108634A BG 10863404 A BG10863404 A BG 10863404A BG 108634 A BG108634 A BG 108634A
- Authority
- BG
- Bulgaria
- Prior art keywords
- active compound
- pharmacologically active
- present
- compounds
- mammal
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 239000007972 injectable composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 abstract 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 abstract 1
- 239000004100 Oxytetracycline Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 229960002464 fluoxetine Drugs 0.000 abstract 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 abstract 1
- 229960002237 metoprolol Drugs 0.000 abstract 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 abstract 1
- 229960000625 oxytetracycline Drugs 0.000 abstract 1
- 235000019366 oxytetracycline Nutrition 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 229960005224 roxithromycin Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 abstract 1
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 abstract 1
- 229960000223 tilmicosin Drugs 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 239000003021 water soluble solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34362501P | 2001-10-19 | 2001-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG108634A true BG108634A (en) | 2005-04-30 |
Family
ID=23346878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG108634A BG108634A (en) | 2001-10-19 | 2004-03-16 | Injectable compositions for the controlled delivery of pharmacologically active compound |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US6887487B2 (enExample) |
| EP (1) | EP1446103B1 (enExample) |
| JP (1) | JP4850390B2 (enExample) |
| CN (2) | CN101785861B (enExample) |
| AU (1) | AU2002335077B2 (enExample) |
| BG (1) | BG108634A (enExample) |
| BR (1) | BRPI0213425B8 (enExample) |
| CA (1) | CA2463896C (enExample) |
| ES (1) | ES2561108T3 (enExample) |
| IL (1) | IL160282A (enExample) |
| MX (1) | MXPA04003608A (enExample) |
| NZ (1) | NZ531460A (enExample) |
| PL (1) | PL211116B1 (enExample) |
| RU (1) | RU2292871C2 (enExample) |
| WO (1) | WO2003034988A2 (enExample) |
| ZA (1) | ZA200401076B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887487B2 (en) * | 2001-10-19 | 2005-05-03 | Idexx Laboratories, Inc. | Injectable compositions for the controlled delivery of pharmacologically active compound |
| US6946137B2 (en) * | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| US20070060604A1 (en) * | 2002-03-25 | 2007-03-15 | Council Of Scientific And Industrial Research | Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment |
| US20050049210A1 (en) * | 2003-08-27 | 2005-03-03 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| US7858115B2 (en) | 2004-06-24 | 2010-12-28 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
| US7854943B2 (en) | 2004-06-24 | 2010-12-21 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
| US7618651B2 (en) | 2004-06-24 | 2009-11-17 | Idexx Laboratories | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same |
| EP1804771A2 (en) * | 2004-10-28 | 2007-07-11 | Idexx Laboratories, Inc. | Compositions for controlled delivery of pharmaceutically active compounds |
| US7282487B2 (en) * | 2004-10-28 | 2007-10-16 | Idexx Laboratories | Method for treating bacterial infections in horses or pigs with tilmicosin |
| WO2007016153A2 (en) * | 2005-07-28 | 2007-02-08 | Eli Lilly And Company | Tilmicosin formulation |
| US8114440B2 (en) * | 2005-11-16 | 2012-02-14 | Idexx Laboratories Inc. | Pharmaceutical compositions for the administration of aptamers |
| US7754679B2 (en) * | 2005-11-16 | 2010-07-13 | Idexx Laboratories, Inc. | Pharmaceutical compositions for the administration of aptamers |
| US20070196398A1 (en) * | 2006-02-17 | 2007-08-23 | Murthy Yerramilli V S | Fluoroquinolone fatty acid salt compositions |
| US7973022B2 (en) * | 2006-02-17 | 2011-07-05 | Idexx Laboratories, Inc. | Fluoroquinolone carboxylic acid salt compositions |
| US20090239891A1 (en) * | 2006-03-01 | 2009-09-24 | Shukla Atul J | Sustained Release Dosage Forms of Analgesic Medications |
| EP2162540A2 (en) | 2007-05-22 | 2010-03-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| US20090005326A1 (en) * | 2007-06-26 | 2009-01-01 | Idexx Laboratories, Inc. | Single dose roxithromycin |
| US8828960B2 (en) * | 2007-07-17 | 2014-09-09 | Idexx Laboratories, Inc. | Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds |
| USRE46397E1 (en) | 2007-11-07 | 2017-05-09 | Svip5 Llc | Slow release of organic salts of local anesthetics for pain relief |
| CN101496811B (zh) * | 2008-12-24 | 2011-03-16 | 天津瑞普生物技术股份有限公司 | 一种可溶且稳定的替米考星组合物 |
| CN101690713B (zh) * | 2009-09-28 | 2011-12-28 | 普莱柯生物工程股份有限公司 | 一种喹诺酮注射液的制备方法 |
| US20110177157A1 (en) * | 2010-01-19 | 2011-07-21 | Idexx Laboratories, Inc. | Compositions for Controlled Delivery of Pharmaceutically Active Compounds |
| SG10201601789TA (en) | 2011-03-16 | 2016-04-28 | Amgen Inc | Potent And Selective Inhibitors Of Nav1.3 And Nav1.7 |
| US20160067347A1 (en) | 2012-12-20 | 2016-03-10 | Amgen Inc. | Apj receptor agonists and uses thereof |
| US10344060B2 (en) | 2013-03-12 | 2019-07-09 | Amgen Inc. | Potent and selective inhibitors of Nav1.7 |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| PT3116475T (pt) | 2014-03-13 | 2020-12-15 | Neuroderm Ltd | Composições de inibidores de dopa-descarboxilase |
| AU2015274574B2 (en) | 2014-06-10 | 2019-10-10 | Amgen Inc. | Apelin polypeptides |
| US11318190B2 (en) | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
| CN108042491B (zh) * | 2018-01-23 | 2021-02-09 | 山东迅达康兽药有限公司 | 一种替米考星纳米乳及其制备方法 |
| US20220202835A1 (en) * | 2019-03-01 | 2022-06-30 | Boehringer Ingelheim Animal Health USA Inc. | Injectable clorsulon compositions, methods and uses thereof |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| CN113730340A (zh) * | 2021-09-17 | 2021-12-03 | 中国药科大学 | 一种注射用脂肪酸缓释组合物及其制备方法和应用 |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB674784A (en) * | 1949-05-25 | 1952-07-02 | Chimiotherapie Lab Franc | Penicillin preparations for injection |
| GB731933A (en) * | 1951-04-28 | 1955-06-15 | Fougera And Company E | Liquid preparations of therapeutically active substances for sub-cutaneous or intramuscular injection |
| US4259331A (en) * | 1979-04-16 | 1981-03-31 | Pfizer Inc. | Oxytetracycline compositions |
| US4298375A (en) | 1979-10-01 | 1981-11-03 | Monsanto Company | 2-Substituted-5-phenyl-4-thiazolecarboxylic acids and their derivatives as safening agents |
| US4820695A (en) | 1982-09-13 | 1989-04-11 | Eli Lilly And Company | C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics |
| DE3248328A1 (de) * | 1982-12-28 | 1984-06-28 | Bayer Ag, 5090 Leverkusen | Schwerloesliche salze von aminoglykosiden sowie diese enthaltende formulierungen mit verzoegerter wirkstoff-freigabe |
| GB8725427D0 (en) * | 1987-10-30 | 1987-12-02 | Lilly Industries Ltd | Somatotropin formulations |
| JPH027314A (ja) | 1988-06-27 | 1990-01-11 | Asahi Denso Kk | スイッチ |
| JPH02115118A (ja) * | 1988-10-24 | 1990-04-27 | Wakunaga Pharmaceut Co Ltd | 注射剤 |
| US5574020A (en) * | 1989-09-28 | 1996-11-12 | Eli Lilly And Company | Tilmicosin formulation |
| US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
| RU2097025C1 (ru) * | 1990-11-06 | 1997-11-27 | Ниппон Синяку Компани, Лимитед | Лиофилизированный препарат жировой эмульсии и способ его получения |
| US5658956A (en) * | 1991-03-01 | 1997-08-19 | Warner-Lambert Company | Bioadhesive-wound healing compositions and methods for preparing and using same |
| GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| SE9202128D0 (sv) * | 1992-07-09 | 1992-07-09 | Astra Ab | Precipitation of one or more active compounds in situ |
| US5817321A (en) * | 1992-10-08 | 1998-10-06 | Supratek Pharma, Inc. | Biological agent compositions |
| NZ250465A (en) * | 1992-12-21 | 1995-10-26 | Lilly Co Eli | Bactericidal composition; contains macrolide antibiotic, use for treating aquatic species |
| US6110905A (en) | 1994-07-09 | 2000-08-29 | Norbrook Laboratories Limited | Long-acting oxytetracycline composition |
| US6333021B1 (en) * | 1994-11-22 | 2001-12-25 | Bracco Research S.A. | Microcapsules, method of making and their use |
| JP3277735B2 (ja) * | 1994-12-07 | 2002-04-22 | 富士レビオ株式会社 | ナフトエ酸誘導体の吸収促進組成物 |
| US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| US6310053B1 (en) | 1995-07-05 | 2001-10-30 | Norbrook Laboratories Limited | Long-acting oxytetracycline composition |
| US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5723447A (en) | 1996-07-02 | 1998-03-03 | Rhone Merieux, Inc. | Water miscible erythromycin solutions |
| US5958888A (en) * | 1996-07-02 | 1999-09-28 | Merial, Inc. | Water miscible macrolide solutions |
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| CA2263411A1 (en) * | 1996-08-12 | 1998-02-19 | Eyal S. Ron | Composition for pharmaceutical applications |
| SE511313C2 (sv) | 1997-01-13 | 1999-09-06 | Gs Dev Ab | Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol |
| US6630168B1 (en) * | 1997-02-20 | 2003-10-07 | Biomedicines, Inc. | Gel delivery vehicles for anticellular proliferative agents |
| US6074657A (en) * | 1997-03-20 | 2000-06-13 | Pharmacia & Upjohn Company | Administration of an injectable antibiotic in the ear of an animal |
| TR199902748T2 (xx) * | 1997-05-06 | 2000-05-22 | Norbrook Laboratories Limited | Uzun s�re etkili antimikrobik maddelerle ilgili geli�meler |
| JPH11171794A (ja) * | 1997-12-04 | 1999-06-29 | Shoji Awazu | 動脈注射製剤 |
| TW565452B (en) | 1998-03-02 | 2003-12-11 | Lilly Co Eli | A pharmaceutical composition for use in inhibiting swine infertility and respiratory syndrome virus (SIRSV) proliferation in swine in need of treatment |
| BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| US6239112B1 (en) * | 1998-07-09 | 2001-05-29 | Merial, Inc. | Water miscible macrolide solutions |
| US6328961B1 (en) | 1998-08-20 | 2001-12-11 | Bristol-Myers Squibb Company | Tyrissamycin antibiotic |
| US6174540B1 (en) * | 1998-09-14 | 2001-01-16 | Merck & Co., Inc. | Long acting injectable formulations containing hydrogenated caster oil |
| US6677321B1 (en) * | 1999-12-09 | 2004-01-13 | Bruce Levin | Methods and compositions for treatment of inflammatory disease |
| AU781682B2 (en) * | 2000-03-20 | 2005-06-09 | Zoetis Services Llc | Sustained-release compositions for parenteral administration |
| US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| US20040033938A1 (en) * | 2000-09-12 | 2004-02-19 | Britten Nancy J. | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
| US20030219461A1 (en) * | 2000-09-12 | 2003-11-27 | Britten Nancy J. | Parenteral combination therapy for infective conditions |
| US6946137B2 (en) * | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| US6887487B2 (en) | 2001-10-19 | 2005-05-03 | Idexx Laboratories, Inc. | Injectable compositions for the controlled delivery of pharmacologically active compound |
| US6790867B2 (en) * | 2002-05-20 | 2004-09-14 | Schering-Plough Animal Health Corporation | Compositions and method for treating infection in cattle and swine |
| US20050049210A1 (en) * | 2003-08-27 | 2005-03-03 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
-
2002
- 2002-10-18 US US10/274,445 patent/US6887487B2/en not_active Expired - Lifetime
- 2002-10-18 CA CA2463896A patent/CA2463896C/en not_active Expired - Lifetime
- 2002-10-18 RU RU2004115103/15A patent/RU2292871C2/ru active
- 2002-10-18 AU AU2002335077A patent/AU2002335077B2/en not_active Expired
- 2002-10-18 NZ NZ531460A patent/NZ531460A/en not_active IP Right Cessation
- 2002-10-18 PL PL368338A patent/PL211116B1/pl unknown
- 2002-10-18 CN CN201010124253.1A patent/CN101785861B/zh not_active Expired - Lifetime
- 2002-10-18 JP JP2003537557A patent/JP4850390B2/ja not_active Expired - Lifetime
- 2002-10-18 ES ES02802160.8T patent/ES2561108T3/es not_active Expired - Lifetime
- 2002-10-18 WO PCT/US2002/033300 patent/WO2003034988A2/en not_active Ceased
- 2002-10-18 EP EP02802160.8A patent/EP1446103B1/en not_active Expired - Lifetime
- 2002-10-18 BR BRPI0213425A patent/BRPI0213425B8/pt not_active IP Right Cessation
- 2002-10-18 CN CNA028192842A patent/CN1607937A/zh active Pending
-
2003
- 2003-03-28 US US10/403,100 patent/US7033599B2/en not_active Expired - Fee Related
-
2004
- 2004-02-09 IL IL160282A patent/IL160282A/en active IP Right Grant
- 2004-02-10 ZA ZA2004/01076A patent/ZA200401076B/en unknown
- 2004-03-16 BG BG108634A patent/BG108634A/xx unknown
- 2004-04-16 MX MXPA04003608A patent/MXPA04003608A/es active IP Right Grant
-
2005
- 2005-03-25 US US11/088,922 patent/US7404964B2/en not_active Expired - Lifetime
-
2007
- 2007-01-31 US US11/700,068 patent/US20070141162A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7404964B2 (en) | 2008-07-29 |
| BR0213425A (pt) | 2004-12-14 |
| CN1607937A (zh) | 2005-04-20 |
| EP1446103B1 (en) | 2015-12-23 |
| WO2003034988A2 (en) | 2003-05-01 |
| RU2004115103A (ru) | 2005-03-20 |
| US20050163859A1 (en) | 2005-07-28 |
| PL211116B1 (pl) | 2012-04-30 |
| JP2005506992A (ja) | 2005-03-10 |
| US20070141162A1 (en) | 2007-06-21 |
| EP1446103A4 (en) | 2011-01-12 |
| US20030130211A1 (en) | 2003-07-10 |
| CA2463896A1 (en) | 2003-05-01 |
| US6887487B2 (en) | 2005-05-03 |
| ZA200401076B (en) | 2005-06-29 |
| EP1446103A2 (en) | 2004-08-18 |
| CA2463896C (en) | 2010-05-04 |
| BRPI0213425B8 (pt) | 2021-05-25 |
| NZ531460A (en) | 2005-05-27 |
| JP4850390B2 (ja) | 2012-01-11 |
| RU2292871C2 (ru) | 2007-02-10 |
| ES2561108T3 (es) | 2016-02-24 |
| US20050075296A1 (en) | 2005-04-07 |
| CN101785861A (zh) | 2010-07-28 |
| AU2002335077B2 (en) | 2006-09-07 |
| IL160282A (en) | 2009-11-18 |
| WO2003034988A3 (en) | 2003-07-31 |
| MXPA04003608A (es) | 2004-07-27 |
| PL368338A1 (en) | 2005-03-21 |
| BRPI0213425B1 (pt) | 2020-01-28 |
| US7033599B2 (en) | 2006-04-25 |
| CN101785861B (zh) | 2014-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG108634A (en) | Injectable compositions for the controlled delivery of pharmacologically active compound | |
| JP2005506992A5 (enExample) | ||
| KR100802366B1 (ko) | 풀베스트란트 제제 | |
| DE60117362T2 (de) | Parenteral anzuwendendes bisphosphonathaltiges arzneimittel | |
| WO2004091541A3 (en) | Methods for the controlled delivery of pharmacologically active compounds | |
| ES2253423T3 (es) | Formulacion de un ester de testosterona para uso humano. | |
| DE2817335A1 (de) | Antibiotische tetracyclinhaltige mittel | |
| BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| BRPI0512177A (pt) | formulação de liberação modificada de memantina | |
| JP2007506766A5 (enExample) | ||
| CA2304096A1 (en) | Sustained-release liposomal anesthetic compositions | |
| MXPA05012791A (es) | Formulacion sostenida que contiene dimeticona. | |
| WO2010103544A3 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| EP1524983B1 (de) | Zusammensetzung, enthaltend ein androgenes 11-b-halogensteroid und ein gestagen sowie m nnliches kontrazeptivum auf basis dieser zusammensetzung | |
| JPH01268633A (ja) | Ｌ−ドーパの直腸被吸収性形態 | |
| WO2005025488A3 (en) | Methods for the controlled delivery of pharmacologically active compounds | |
| US20040171631A1 (en) | Orally administered analgesic compositions containing nalbuphine | |
| CN1582170B (zh) | 扑热息痛的肠胃外组合物 | |
| AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
| ES2204958T3 (es) | Compuesto de oxitetraciclina de largo efecto. | |
| JP2007503433A5 (enExample) | ||
| ES2021904A6 (es) | Procedimiento para preparar una composicion farmaceutica a base de un acido piperacinacarboxilico. | |
| PE20020903A1 (es) | Metodo para prevenir la diarrea | |
| HRP20100212T1 (hr) | Pripravci s povećanim elastificirajućim učinkom |